All In Biotech

NDA 214665 · Amgen INC

Lumakras

Sotorasib · Oral

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

CDER novel approval, May 28, 2021: To treat types of non-small cell lung cancer

Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

May 28, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

67

5 Phase 3, 17 recruiting

FAERS reports

3,470

2,851 serious, 824 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 3, 2026.

LUMAKRAS is an inhibitor of the RAS GTPase family indicated for: KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. ( 1.2 ) 1.1 KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) LUMAKRAS as a single agent is indicated for the treatment of adult patients with KRAS G12C -mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test [see Dosage and Administration (2.1) ] , who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) LUMAKRAS, in combination with panitumumab, is indicated for the treatment of adult patients with KRAS G12C -mutated metastatic...

Mechanism: Sotorasib is an inhibitor of KRAS G12C, a tumor-restricted, mutant-oncogenic form of the RAS GTPase, KRAS. Sotorasib forms an irreversible, covalent bond with the unique cysteine of KRAS G12C, locking the protein in an inactive state that prevents downstream signaling without affecting wild-type KRAS. Sotorasib blocked KRAS signaling, inhibited cell growth, and promoted apoptosis only in KRAS G12C tumor cell lines. Sotorasib inhibited KRAS G12C in vitro and in vivo with minimal detectable off-target activity. In mouse tumor xenograft models, sotorasib-treatment led to tumor regressions and...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 16, 2025 Supplement 9 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
  • May 28, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
3 products under this application
  • LUMAKRAS · SOTORASIB 320MG · TABLET, ORAL · Prescription
  • LUMAKRAS · SOTORASIB 240MG · TABLET, ORAL · Prescription
  • LUMAKRAS · SOTORASIB 120MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sotorasib" as an intervention, any sponsor and status, largest first.

All 67 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • non-small cell lung cancer520
  • death415
  • disease progression348
  • diarrhoea334
  • off label use268
  • fatigue119
  • nausea119
  • hepatotoxicity103
  • hepatic function abnormal101
  • non-small cell lung cancer metastatic98
  • lung neoplasm malignant85
  • alanine aminotransferase increased81

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2021198
2022714
20231,226
2024545
2025381
2026406

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lumakras (Sotorasib)

2024 spending

$154M

Beneficiaries

1,563

8,675 claims

Per beneficiary

$98,285

$146.16 per unit

View as table
YearSpending
2020$0
2021$35,800,207
2022$123,593,806
2023$140,234,716
2024$153,620,121

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 34 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.